Mixing Business And Philanthropy Yields Returns For Glaxo In Africa
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline is having success with its "hybrid" approach in Africa, combining no-nonsense business with the aim of improving access to medicines there – in part through deeply discounted prices, measuring managers’ sales performances by the amount of drugs sold, rather than profits, and reinvesting in health infrastructure.
You may also be interested in...
GlaxoSmithKline Offering Free Access to Potential Malaria Compounds
In another effort to boost development of malaria medicines GlaxoSmithKline is providing free public access to its library of 13,500 compounds that have shown some activity against the disease
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.